Reimagining Medicine for Lung Cancer
Click to explore
Disease Education
MOA Resources
Novartis Clinical Trials
-
Disease Education
Pro-tumor inflammation (PTI) Mechanism of Disease
-
Lung Cancer Mechanism of Action Resources
Canakinumab Mechanism of Action
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
-
Featured Clinical Trials & Investigational Compounds
Clinical TrialsCANOPY-A
Capmatinib + Spartalizumab vs Docetaxel in Locally Advanced or Metastatic NSCLC
Capmatinib Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC with PD-L1 > 50%
Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients with MET Exon 14 Skipping MutationsCompound CardsIL-1b antibody: Canakinumab (ACZ885)MET inhibitor: Capmatinib (INC280)PD-1 monoclonal antibody: Spartalizumab (PDR001)All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
